Who are the top shareholders of the Aarti Pharma?

The top shareholders of Aarti Pharma include promoter Rashesh Chandrakant Gogri with 4.23%, Life Insurance Corporation of India at 6.06%, 109 Foreign Institutional Investors holding 7.36%, mutual funds at 0.78%, and individual investors collectively owning 34.1%.

The top shareholders of Aarti Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Rashesh Chandrakant Gogri, owning 4.23%. Among public shareholders, the Life Insurance Corporation of India is the largest, holding 6.06%. Additionally, institutional investors are represented by 109 Foreign Institutional Investors (FIIs) with a combined holding of 7.36%, and mutual funds hold 0.78% through seven schemes. Individual investors collectively hold 34.1% of the shares.

how big is Aarti Pharma?

As of Jun 06, Aarti Pharmalabs Ltd has a market capitalization of 8,323.00 Cr and reported net sales of 2,115.08 Cr and net profit of 272.40 Cr over the latest four quarters.

Market Cap: <BR>As of Jun 06, Aarti Pharmalabs Ltd has a market capitalization of 8,323.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest 4 quarters, Aarti Pharmalabs Ltd reported a sum of Net Sales of 2,115.08 Cr and a sum of Net Profit of 272.40 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: <BR>This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 1,757.04 Cr, and the Total Assets amount to 2,582.11 Cr.

Has Aarti Pharma declared dividend?

Yes, Aarti Pharma has declared a dividend of 50%, amounting to ₹2.5 per share, with an ex-date of February 14, 2025. The company has shown strong total returns, particularly 55.18% over the past year and 132.53% over the past two years.

Aarti Pharma has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 2.5<BR>- Ex-date: 14 Feb 25<BR><BR>Dividend Yield: 0.38%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Aarti Pharma has achieved a price return of 43.95%, a dividend return of 0.40%, resulting in a total return of 44.35%.<BR><BR>Over the past year, the company has seen a price return of 54.6%, with a dividend return of 0.58%, leading to a total return of 55.18%.<BR><BR>In the 2-year period, the price return was 131.13%, the dividend return was 1.40%, culminating in a total return of 132.53%.<BR><BR>For the 3-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Similarly, in the 4-year and 5-year periods, there were no price or dividend returns, both resulting in total returns of 0.0%.<BR><BR>Overall, Aarti Pharma has declared a significant dividend and has shown strong total returns over the shorter periods, particularly in the 1-year and 2-year spans, indicating positive performance and shareholder value creation.

Who are the peers of the Aarti Pharma?

Aarti Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Strides Pharma, FDC, SPARC, Supriya Lifesci, and Innova Captab. Aarti Pharma has good management risk and capital structure, with a 1-year return of 58%, higher than SPARC but lower than Supriya Lifesci's 101.13%.

Peers: The peers of Aarti Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Strides Pharma, FDC, SPARC, Supriya Lifesci., and Innova Captab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Supriya Lifesci., while Good management risk is found at Divi's Lab., Torrent Pharma, and Aarti Pharma. Below Average management risk is noted at Strides Pharma and SPARC. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Aarti Pharma, FDC, Strides Pharma, and SPARC, and the rest. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Aarti Pharma, FDC, and Supriya Lifesci., while Good capital structure is found at Torrent Pharma, and Below Average capital structure is noted at Strides Pharma and SPARC.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Supriya Lifesci. at 101.13%, while the lowest is SPARC at -7.40%. Aarti Pharma's 1-year return is 58.00%, which is significantly higher than SPARC's but lower than Supriya Lifesci.'s. Additionally, the peers with negative six-month returns are Strides Pharma and FDC.

Who are in the management team of Aarti Pharma?

As of March 2023, Aarti Pharma's management team includes Rashesh C Gogri (Chairman), Hetal Gogri Gala (Vice Chairperson & Managing Director), Narendra Jagannath Salvi (Managing Director), and several non-executive and independent directors. The team combines executive leadership with independent oversight for effective governance.

As of March 2023, the management team of Aarti Pharma includes the following members:<BR><BR>1. Rashesh C Gogri - Chairman<BR>2. Hetal Gogri Gala - Vice Chairperson & Managing Director<BR>3. Narendra Jagannath Salvi - Managing Director<BR>4. Rajendra V Gogri - Non-Executive & Non-Independent Director<BR>5. Parimal H Desai - Non-Executive Director<BR>6. Bhavesh R Vora - Independent Director<BR>7. Vinay Gopal Nayak - Independent Director<BR>8. Vilas G Gaikar - Independent Director<BR>9. Jeenal Savla - Independent Director<BR>10. Rupal Vora - Independent Director<BR><BR>This team comprises a mix of executive and non-executive directors, with several independent directors contributing to the governance of the company.

What does Aarti Pharma do?

Aarti Pharmalabs Ltd manufactures Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, and New Chemical Entities (NCE) in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of ₹5,638 Cr and a net profit of ₹883 Cr, with a market cap of ₹8,574 Cr.

Overview: <BR>Aarti Pharmalabs Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives, operating within the Pharmaceuticals & Biotechnology industry as a Mid Cap company.<BR><BR>History: <BR>Aarti Pharmalabs Ltd was incorporated as a Public Limited Company in 2019 and changed its name from Aarti Organics Limited to Aarti Pharmachem Limited on July 1, 2021. The most recent quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 5,638 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 883 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 8,574 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.37% <BR>Debt-Equity: 0.18 <BR>Return on Equity: 13.69% <BR>Price to Book: 4.31 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

When is the next results date for Aarti Pharma?

The next results date for Aarti Pharma is 09 November 2025.

The next results date for Aarti Pharma is scheduled for 09 November 2025.

Are Aarti Pharma latest results good or bad?

Aarti Pharma's latest results are concerning, with a 43.97% decline in net profit and a 31.50% drop in net sales quarter-on-quarter, overshadowing a stable operating margin. The market reacted negatively, and governance concerns arise from the near-complete exit of promoters, indicating potential challenges for future growth.

Aarti Pharma's latest results are concerning, reflecting a significant decline in both net profit and net sales. In Q2 FY26, the company reported a net profit of ₹49.50 crore, which is a sharp decrease of 43.97% quarter-on-quarter and 10.73% year-on-year. Similarly, net sales fell to ₹386.19 crore, down 31.50% from the previous quarter and 30.48% compared to the same quarter last year.<BR><BR>While there are some positive aspects, such as maintaining an operating margin of 24.66%—which shows some operational efficiency—these gains are overshadowed by the substantial revenue contraction. The market reacted negatively, with the stock trading below key moving averages and experiencing negative returns across various timeframes.<BR><BR>Additionally, the near-complete exit of promoters raises governance concerns, further complicating the company's outlook. Overall, the results indicate operational challenges that could affect the sustainability of growth moving forward.

Is Aarti Pharma overvalued or undervalued?

As of November 10, 2025, Aarti Pharma is fairly valued with a PE ratio of 28.73, lower than some peers like Sun Pharma and Divi's Lab but higher than Cipla, and has shown mixed performance with recent declines against the Sensex but a positive year-to-date return of 10.59%.

As of 10 November 2025, Aarti Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics, with a PE ratio of 28.73, an EV to EBITDA of 16.31, and a PEG ratio of 5.64. These ratios suggest that while the company is not undervalued, it is also not overvalued compared to its peers.<BR><BR>In comparison to its industry peers, Aarti Pharma's PE ratio is lower than that of Sun Pharma, which stands at 35.15, and significantly lower than Divi's Lab at 71.55, both of which are considered expensive. However, it is higher than Cipla's attractive valuation with a PE of 22.45. The stock has underperformed against the Sensex over the past week and month, with returns of -11.37% and -8.71%, respectively, although it has outperformed on a year-to-date basis with a return of 10.59%. Overall, Aarti Pharma appears to be fairly valued in the current market context.

How has been the historical performance of Aarti Pharma?

Aarti Pharma has shown significant growth from March 2022 to March 2025, with net sales increasing from 1,199.94 Cr to 2,115.07 Cr, and profit after tax rising from 122.25 Cr to 272.40 Cr, indicating improved profitability and operational efficiency. Total assets and liabilities grew proportionally, while cash flow from operations improved from -43.00 Cr to 331.00 Cr.

Answer:<BR>The historical performance of Aarti Pharma shows significant growth in net sales and profitability over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Aarti Pharma's net sales increased from 1,199.94 Cr in March 2022 to 2,115.07 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 1,199.94 Cr in March 2022 to 2,115.07 Cr in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from 206.95 Cr in March 2022 to 474.48 Cr in March 2025, indicating improved operational efficiency. Profit before tax rose from 155.38 Cr in March 2022 to 360.69 Cr in March 2025, while profit after tax increased from 122.25 Cr to 272.40 Cr in the same period, showcasing a consistent enhancement in profitability. The earnings per share (EPS) grew from 26.83 in March 2022 to 30.05 in March 2025, further highlighting the company's financial health. On the balance sheet, total assets increased from 2,039.90 Cr in March 2022 to 2,906.41 Cr in March 2025, with total liabilities also rising from 2,039.90 Cr to 2,906.41 Cr, indicating a proportional growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching 331.00 Cr in March 2025, compared to a negative cash flow of 43.00 Cr in March 2022, reflecting better cash management and operational performance.

Should I buy, sell or hold Aarti Pharma?

Which are the latest news on Aarti Pharma?

Why is Aarti Pharma falling/rising?

As of 03-Dec, Aarti Pharmalabs Ltd's stock price is rising to Rs 710.70, reflecting a 2.0% increase. This rise is driven by strong sector performance and attractive valuation metrics, despite concerns over long-term growth and recent declines in net sales.

As of 03-Dec, Aarti Pharmalabs Ltd's stock price is rising, currently at Rs 710.70, reflecting an increase of Rs 13.95 or 2.0%. This upward movement is notable as the stock has outperformed its sector by 2.01% today. The stock reached an intraday high of Rs 712.2, indicating positive trading momentum.<BR><BR>Despite a recent decline in net sales and negative results in the last two quarters, the company maintains a strong ability to service its debt, evidenced by a low Debt to EBITDA ratio of 1.03 times. Additionally, the stock is trading at a discount compared to its peers' average historical valuations, which may attract investors looking for value. Over the past year, the stock has generated a return of 7.85%, and while its profits have only risen by 5.1%, the attractive valuation metrics, such as a ROCE of 13.2 and a PEG ratio of 5.3, suggest potential for future growth.<BR><BR>However, it is important to note that there are concerns regarding long-term growth, as net sales have only grown at an annual rate of 1.37% over the last five years, and the recent drop in sales of 14% has raised red flags. Furthermore, promoter confidence appears to be waning, with a decrease in their stake by 0.84% in the previous quarter.<BR><BR>In summary, the stock's rise today can be attributed to its strong performance relative to the sector, attractive valuation metrics, and a positive trading environment, despite underlying concerns about long-term growth and recent negative financial results.

Is Aarti Pharma technically bullish or bearish?

As of December 3, 2025, the market trend is mildly bearish, influenced by bearish signals from the MACD and moving averages, despite some bullish momentum from the RSI and mixed signals from the Bollinger Bands and KST.

As of 3 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD indicating bearish momentum and the daily moving averages also reflecting a bearish trend. The weekly RSI shows bullish momentum, but this is countered by the overall bearish signals from the MACD and moving averages. The Bollinger Bands are mildly bearish on the weekly timeframe, while the KST indicates bullishness, creating mixed signals. Overall, the lack of a definitive trend in Dow Theory further supports a neutral outlook, but the prevailing indicators lean towards a mildly bearish stance.